Cargando…
Addition of HER2 and CD44 to (18)F-FDG PET–based clinico-radiomic models enhances prediction of neoadjuvant chemoradiotherapy response in esophageal cancer
OBJECTIVES: To assess the complementary value of human epidermal growth factor receptor 2 (HER2)-related biological tumor markers to clinico-radiomic models in predicting complete response to neoadjuvant chemoradiotherapy (NCRT) in esophageal cancer patients. METHODS: Expression of HER2 was assessed...
Autores principales: | Beukinga, Roelof J., Wang, Da, Karrenbeld, Arend, Dijksterhuis, Willemieke P. M., Faber, Hette, Burgerhof, Johannes G. M., Mul, Véronique E. M., Slart, Riemer H. J. A., Coppes, Robert P., Plukker, John Th. M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8043921/ https://www.ncbi.nlm.nih.gov/pubmed/33151397 http://dx.doi.org/10.1007/s00330-020-07439-8 |
Ejemplares similares
-
Effect of Extending the Original Eligibility Criteria for the CROSS Neoadjuvant Chemoradiotherapy on Toxicity and Survival in Esophageal Cancer
por: de Heer, E. C., et al.
Publicado: (2017) -
Hedgehog Pathway as a Potential Intervention Target in Esophageal Cancer
por: Wang, Da, et al.
Publicado: (2019) -
Potential Predictive Immune and Metabolic Biomarkers of Tumor Microenvironment Regarding Pathological and Clinical Response in Esophageal Cancer After Neoadjuvant Chemoradiotherapy: A Systematic Review
por: Wang, H. H., et al.
Publicado: (2023) -
Prognostic Value of the Circumferential Resection Margin in Esophageal Cancer Patients After Neoadjuvant Chemoradiotherapy
por: Hulshoff, J. B., et al.
Publicado: (2015) -
Better Survival in Patients with Esophageal Cancer After Surgical Treatment in University Hospitals: A Plea for Performance by Surgical Oncologists
por: Verhoef, Christian, et al.
Publicado: (2007)